295 related articles for article (PubMed ID: 10768568)
1. PET: the merging of biology and imaging into molecular imaging.
Phelps ME
J Nucl Med; 2000 Apr; 41(4):661-81. PubMed ID: 10768568
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography provides molecular imaging of biological processes.
Phelps ME
Proc Natl Acad Sci U S A; 2000 Aug; 97(16):9226-33. PubMed ID: 10922074
[TBL] [Abstract][Full Text] [Related]
4. Applications of PET in lung cancer.
Al-Sugair A; Coleman RE
Semin Nucl Med; 1998 Oct; 28(4):303-19. PubMed ID: 9800237
[TBL] [Abstract][Full Text] [Related]
5. PET in oncology: will it replace the other modalities?
Hoh CK; Schiepers C; Seltzer MA; Gambhir SS; Silverman DH; Czernin J; Maddahi J; Phelps ME
Semin Nucl Med; 1997 Apr; 27(2):94-106. PubMed ID: 9144854
[TBL] [Abstract][Full Text] [Related]
6. PET in lung cancer.
Coleman RE
J Nucl Med; 1999 May; 40(5):814-20. PubMed ID: 10319756
[TBL] [Abstract][Full Text] [Related]
7. Imaging in lung cancer: positron emission tomography scan.
Vansteenkiste JF
Eur Respir J Suppl; 2002 Feb; 35():49s-60s. PubMed ID: 12064681
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography imaging of regional cerebral glucose metabolism.
Alavi A; Dann R; Chawluk J; Alavi J; Kushner M; Reivich M
Semin Nucl Med; 1986 Jan; 16(1):2-34. PubMed ID: 2935938
[TBL] [Abstract][Full Text] [Related]
9. Abass Alavi: A giant in Nuclear Medicine turns 80 and is still going strong!
Høilund-Carlsen PF
Hell J Nucl Med; 2018; 21(1):85-87. PubMed ID: 29550853
[TBL] [Abstract][Full Text] [Related]
10. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer.
Adams S; Baum RP; Stuckensen T; Bitter K; Hör G
Eur J Nucl Med; 1998 Sep; 25(9):1255-60. PubMed ID: 9724374
[TBL] [Abstract][Full Text] [Related]
11. The impact of
Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A
Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508
[TBL] [Abstract][Full Text] [Related]
12. Value of whole-body FDG PET in management of lung cancer.
Higashi K; Matsunari I; Ueda Y; Ikeda R; Guo J; Oguchi M; Tonami H; Yamamoto I
Ann Nucl Med; 2003 Feb; 17(1):1-14. PubMed ID: 12691125
[TBL] [Abstract][Full Text] [Related]
13. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer.
Mahner S; Schirrmacher S; Brenner W; Jenicke L; Habermann CR; Avril N; Dose-Schwarz J
Ann Oncol; 2008 Jul; 19(7):1249-1254. PubMed ID: 18356138
[TBL] [Abstract][Full Text] [Related]
14. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography.
Meltzer CC; Luketich JD; Friedman D; Charron M; Strollo D; Meehan M; Urso GK; Dachille MA; Townsend DW
Clin Nucl Med; 2000 Nov; 25(11):882-7. PubMed ID: 11079584
[TBL] [Abstract][Full Text] [Related]
15. [Molecular imaging by PET/SPECT].
Ono M
Yakugaku Zasshi; 2009 Mar; 129(3):279-87. PubMed ID: 19252385
[TBL] [Abstract][Full Text] [Related]
16. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures.
Schirrmeister H; Kühn T; Guhlmann A; Santjohanser C; Hörster T; Nüssle K; Koretz K; Glatting G; Rieber A; Kreienberg R; Buck AC; Reske SN
Eur J Nucl Med; 2001 Mar; 28(3):351-8. PubMed ID: 11315604
[TBL] [Abstract][Full Text] [Related]
17. Staging of recurrent and advanced lung cancer with 18F-FDG PET in a coincidence technique (hybrid PET).
Schmid RA; Hautmann H; Poellinger B; Kellner W; Moisseev A; Brinkbaeumer K; Weiss M; Hahn K; Dresel S
Nucl Med Commun; 2003 Jan; 24(1):37-45. PubMed ID: 12501018
[TBL] [Abstract][Full Text] [Related]
18. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
Shen YY; Kao A; Yen RF
Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
[TBL] [Abstract][Full Text] [Related]
19. PET and PET-CT for evaluation of colorectal carcinoma.
Delbeke D; Martin WH
Semin Nucl Med; 2004 Jul; 34(3):209-23. PubMed ID: 15202102
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of positron emission tomography for the detection of melanoma metastases.
Holder WD; White RL; Zuger JH; Easton EJ; Greene FL
Ann Surg; 1998 May; 227(5):764-9; discussion 769-71. PubMed ID: 9605668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
